Irritable bowel syndrome with constipation (IBS-C) is a type of IBS, a condition that causes different digestive symptoms. The main symptom of IBS-C is constipation, with infrequent, hardened bowel ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Treatments increase fluid in the intestines and stimulate bowel movements Medically reviewed by Lindsay Cook, PharmD Most of the medications for constipation-predominant irritable bowel syndrome ...

For millions of Americans, bathroom trips bring anxiety rather than relief. Irritable bowel syndrome with constipation (IBS-C) impacts approximately one-third of all IBS cases, causing physical ...

Constipation Treatment Market Constipation Treatment Market Dublin, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The "Constipation ...

IBS is a chronic gut disorder with discomfort and bowel changes, but no visible damage. IBS is categorized by bowel habits: constipation (IBS-C), diarrhea (IBS-D), mixed (IBS-M), and post-infectious.

Ardelyx introduced Ibsrela into the well-established IBS-C market and implemented its strategy to attain consistent market. The prolonged absence of effective treatment choices for IBS-C patients ...

Approximately 2% of patients with irritable bowel syndrome (IBS) have a mutation of the SCN5A gene that disrupts sodium channel function, according to a genotype analysis published online March 10 in ...

Ardelyx, Inc. announced that it will present data on its innovative IBSRELA® (tenapanor) at the Digestive Disease Week Conference in San Diego from May 3-6, 2025. IBSRELA is FDA-approved for treating ...

The "Constipation Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Constipation Treatment was valued at US$19.5 Billion in 2024 ...

Exocrine pancreatic insufficiency (EPI) and irritable bowel syndrome (IBS) are gastrointestinal (GI) conditions that share certain symptoms, such as abdominal pain, bloating, and changes to bowel ...